全球前列腺癌治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计摄护腺癌治疗市场将从 2025 年的 200.2 亿美元成长到 2034 年的 447.9 亿美元，2026 年至 2034 年的复合年增长率为 9.36%。

由于全球前列腺癌发生率不断上升，全球前列腺癌治疗市场正经历显着成长。人口老化和诊断筛检的进步推动了治疗率的提高。荷尔蒙疗法、化疗和标靶治疗的进步正在促进市场扩张。人们对早期检测意识的提高也进一步支撑了市场需求。

成长要素包括新型免疫疗法和精准医疗方法的开发。生技和製药公司对研发的投入正在加速创新。发展中地区医疗保健服务的普及也促进了治疗方法的推广。此外，政府的支持措施和癌症防治宣传活动也为稳定成长做出了贡献。

前景依然乐观，这得益于正在进行的临床试验中引入的先进治疗方案。联合治疗和个人化治疗策略将改善患者的治疗效果。全球医疗保健支出的成长预计将支撑市场的持续扩张。在医疗创新的驱动下，前列腺癌药物市场预计将继续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球前列腺癌治疗市场：依疗法分类

• 市场分析、洞察与预测
• 荷尔蒙疗法
• 化疗
• 免疫疗法
• 标靶治疗
• 其他的

第五章 全球前列腺癌治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 雄性激素受体抑制剂
• GnRH受体拮抗剂
• PARP抑制剂
• 免疫查核点抑制剂
• 其他的

第六章：全球前列腺癌治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射药物

第七章 全球前列腺癌治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球前列腺癌治疗市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Dendreon Pharmaceuticals LLC
  • Exelixis, Inc
  • Ferring BV
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sumitomo Pharma AmericaInc
  • Takeda Pharmaceutical Company Limited
  • Tolmar Inc

The Prostate Cancer Therapeutics Market size is expected to reach USD 44.79 Billion in 2034 from USD 20.02 Billion (2025) growing at a CAGR of 9.36% during 2026-2034.

The Global Prostate Cancer Therapeutics market has experienced notable growth due to increasing incidence of prostate cancer worldwide. Aging populations and improved diagnostic screening have contributed to rising treatment rates. Pharmaceutical advancements in hormonal therapy, chemotherapy, and targeted treatments have strengthened market expansion. Growing awareness about early detection further supports demand.

Growth drivers include development of novel immunotherapies and precision medicine approaches. Research investments by biotechnology and pharmaceutical companies accelerate innovation. Expanding healthcare access in developing regions also enhances treatment availability. Additionally, supportive government initiatives and cancer awareness campaigns contribute to steady growth.

Future prospects remain promising as ongoing clinical trials introduce advanced therapeutic options. Combination therapies and personalized treatment strategies will improve patient outcomes. Rising healthcare expenditure globally is expected to support sustained market expansion. The prostate cancer therapeutics market is poised for continued development driven by medical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Other

By Drug Class

• Androgen receptor inhibitors
• GnRH Receptor Antagonist
• PARP Inhibitor
• Immune Checkpoint Inhibitors
• Other

By Route Of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, Dendreon Pharmaceuticals LLC, Exelixis, Inc, Ferring BV, GlaxoSmithKline Plc, Ipsen Pharma, Johnson Johnson, Novartis AG, Pfizer Inc, Sanofi SA, Sumitomo Pharma America, Inc, Takeda Pharmaceutical Company Limited, Tolmar Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy
• 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Androgen receptor inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. GnRH Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. PARP Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Immune Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy
  • 8.2.2 By Drug Class
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy
  • 8.3.2 By Drug Class
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy
  • 8.4.2 By Drug Class
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy
  • 8.5.2 By Drug Class
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy
  • 8.6.2 By Drug Class
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PROSTATE CANCER THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma Inc
  • 10.2.2 AstraZeneca Plc
  • 10.2.3 Bayer AG
  • 10.2.4 Dendreon Pharmaceuticals LLC
  • 10.2.5 Exelixis, Inc
  • 10.2.6 Ferring B.V
  • 10.2.7 GlaxoSmithKline Plc
  • 10.2.8 Ipsen Pharma
  • 10.2.9 Johnson & Johnson
  • 10.2.10 Novartis AG
  • 10.2.11 Pfizer Inc
  • 10.2.12 Sanofi S.A
  • 10.2.13 Sumitomo Pharma AmericaInc
  • 10.2.14 Takeda Pharmaceutical Company Limited
  • 10.2.15 Tolmar Inc